Pancreatic Adenocarcinoma

Signet-Ring / Poorly Cohesive adenocarcinoma of pancreas, No CDH1 mutations in this highly aggressive pancreatic cancer variant (unlike gastric signet ring cell cancers). Great images. (@RZitwer)

It is easily worth 300 bucks to me to know I definitely don't have a 3cm pancreatic adenocarcinoma in the body of my pancreas (@2_trenchcoat)

On SurgOnc Today, @drsuswarner, discusses various scenarios and patient responses when considering resection in patients with pancreatic adenocarcinoma. https://t.co/ZdUuDzqtSU @AlexParikhMD @FlavioRochaMD @HalletJulie (@SocSurgOnc)

On SurgOnc Today, @AlexParikhMD and @HalletJulie, are joined by @FlavioRochaMD, and @drsuswarner to discuss important aspects of neoadjuvant therapy for pancreatic adenocarcinoma. #HPB https://t.co/LmDBRWueO2 (@SocSurgOnc)

Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma ⁦@AnnSurgOncol⁩ ⁦@DWNelsonHPB⁩ ⁦@mkatzmd⁩ https://t.co/cqI4IXQBdM (@SyedAAhmad5)

Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma ⁦@NatureComms⁩ ⁦@AndrewMWaters⁩ ⁦@krushnacpatra⁩ ⁦@Aiims1742⁩ https://t.co/7E1PztRszF (@SyedAAhmad5)

Learn more about a Phase II, open-label pilot study evaluating treatment options for pancreatic adenocarcinoma during this poster session. #ResearchCuresCancer #ASCO23 🕘: 9:00 a.m. EDT/8:00 a.m. CDT 📍: Hall A @anita_turk (@IUCancerCenter)

Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes ⁦@AnnSurgOncol⁩ ⁦@McMastersKelly⁩ ⁦@FlavioRochaMD⁩ ⁦@TheNotoriousHPB⁩ ⁦@AlexParikhMD⁩ https://t.co/Crafdcy8ij (@SyedAAhmad5)

Efficacy of ICIs in MSI-H/dMMR advanced pancreatic adenocarcinoma: an AGEO European Cohort Retrospective, 31 pts ORR➡️48.4% mPFS➡️26.7 mos https://t.co/b41FvjVOMM (@dr_yakupergun)

Interestingly, DLAT correlates with pancreatic adenocarcinoma's progression, chemoresistance, and immune infiltration, providing a valuable reference for new treatment options. @MCWPancProgram @AbiSivaMD @RManochakian https://t.co/1b6FWsaY6d (@Dr_Ivanoncologo)

Just out. Activity of Sotorasib in KRAS G12C-mutated pancreatic adenocarcinoma. One step forward. https://t.co/Mg8C9udg4R (@drgandara)

This study on co-alterations in KRAS-wild type pancreatic adenocarcinomas was well cited during the afternoon session on GI Biomarkers. Highlights importance of comprehensive profiling! From Dr Philip et al @carisls Precision Onc Alliance GI group https://t.co/F2zJHL3NG4 #ASCO22 (@cancerassassin1)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review https://t.co/NawIpKpYso (@VivekSubbiah)

My first thought was of the solid serous cystadenoma of pancreas you shared earlier. Did get duped by the CA-IX though. (@nusrat_xahra)

New insights into Kras-mediated pancreatic adenocarcinoma, including remodeling of the tumor immune microenvironment https://t.co/7aOVmvYjan @UmaMahadevanIBD @IBDMD @RickPeekMD @Aiims1742 (@DouglasCorley)

'Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma' now online in @CCR_AACR - Dr. Philip et al from @carisls GI Precision Oncology Alliance group. "KRAS-WT PDAC represents 10.7% of PDAC";enriched in IO markers" https://t.co/TsFd0X1FQ4 (@cancerassassin1)

I honestly didn't know if I would ever see kras become "druggable" in pancreatic adenocarcinoma Early days but a glimmer of hope in updated CodeBreaK100 data on sotorasib in KRAS G12C–mutant PDAC: 21% ORR but 84% DCR -- disease control matters! #pancsm https://t.co/foBpyNoCOp (@marklewismd)

Me, the son of a preacher man and now a GI oncologist himself, hoping KRAS becomes more druggable in pancreatic adenocarcinoma #pancsm #GI22 (@marklewismd)

#TumorBoardTuesday I am placing my hope on chemotherapy + ATR inhibitor synergy for patients with ATM mutated cancers 👇👇👇 @SamArmstrongMD @Jon_BrodyPhD ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications https://t.co/yF1vEKIevl (@MPishvaian)

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection https://t.co/G6bfGQJtsk #pancreaticcancer @EileenMOReilly @sloan_kettering (@perilonthesea)

#PretTest Q1️⃣ #CME #TumorBoardTuesday 🤔 What percent of pancreatic adenocarcinomas harbor pathogenic/likely pathogenic BRAF 🧬 gene alterations? 👉🏽pretest🔗: https://t.co/mYujiGxVhU ALL🥇CME🔗: https://t.co/63osUKLysL @MPishvaian #PanCan #PancreaticCancer #BRAF (@TumorBoardTues)

If you’re up for browsing a preprint on #PancreaticCancer this weekend, here’s one from my lab: Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma https://t.co/XIfSWTxcY9 (@Aiims1742)

Dr Eileen O'Reilly @sloan_kettering describes druggable kras as the "holy grail" of pancreatic adenocarcinoma pharmacology #pancsm #GDUGI2021 (@marklewismd)

#USCAP2021 abstract "Long Term Survival in Advanced Pancreatic Adenocarcinoma and New Target ID'd by Whole Transcriptome Analysis" by Drs. Rohit Chandwani, Juan M. Mosquera with @DrJonesNauseef @iRonB25 @surrealistNYC @PPJessurun @asbonerw @drallysonocean @ElementoLab @skimomiks (@WCMCPathology)

#USCAP2021 abstract "Long Term Survival in Advanced Pancreatic Adenocarcinoma and New Target ID'd by Whole Transcriptome Analysis" by Drs. Rohit Chandwani, Juan M. Mosquera with @DrJonesNauseef @iRonB25 @surrealistNYC @PPJessurun @asbonerw @drallysonocean @ElementoLab @skimomiks (@EngIPM)

🆕👆🏾Full📝now @CCR_AACR🗞. Our analysis on >3000 #PancreasCancer pts. #VisualAbstract Effect of germline mutations in 🧬HRR #genes on survival➡️pancreatic adenocarcinoma. #PANCSM @OncoAlert ⬆️Younger ⬆️Metastatic ⬆️body/tail ➕many other💡. #BRCA #PALB2 https://t.co/tSNWzvRb5H (@pashtoonkasi)

🆕Out today @CCR_AACR🗞. Our analysis on >3000 #PancreasCancer pts. #VisualAbstract Effect of germline mutations in 🧬HRR #genes on survival➡️pancreatic adenocarcinoma. #PANCSM @OncoAlert ⬆️Younger ⬆️Metastatic ⬆️body/tail ➕many other💡. #BRCA #PALB2 https://t.co/hgL98rbyVv (@pashtoonkasi)

These tend to have more #BRCA DNA 🧬 Repair. Similar to pancreas adenocarcinoma, need to do germline/somatic testing. @Aiims1742 @EileenMOReilly @MPishvaian @ShaalanBeg @DrKelseyKlute @drallysonocean @anup_kasi @NirajGusani. https://t.co/BKIW7Xm6t9 (@pashtoonkasi)

exciting molecular tumor board this morning included CCD6-RET fusion in pancreatic adenocarcinoma and NTRK-ETV6 fusion in triple negative male breast cancer. Seek and ye shall find @oncoalert @mtmdphd @Dr_R_Kurzrock (@antonyruggeri)

Dr. Abdel N. Hosein from @MDAndersonNews presented his research examining the role of Rnf43-loss in Kras-mediated pancreatic adenocarcinoma. #IOYIF20 (@IOYIForum)

Presented during #AACR20: Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. https://t.co/Q1bkzy7JfL (@CCR_AACR)

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection @BasserBRCA @Penn_OCRC https://t.co/uH3NTEFC4y (@ronny_drapkin)